Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues—Revenues	[1]	$ 50,914	$ 91,793	$ 73,636
Revenues—Alliance revenues	[1]	7,582	8,537	7,652
Revenues	[2]	58,496	100,330	81,288
Cost of sales	[3],[4]	(24,954)	(34,344)	(30,821)
Selling, informational and administrative expenses	[3]	(14,771)	(13,677)	(12,703)
Acquired in-process research and development expenses		(194)	(953)	(3,469)
Other income/(deductions)—net		835	(217)	4,878
Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues—Revenues	[5]	212	437	590
Revenues—Alliance revenues	[6]	7,582	8,537	7,652
Revenues		7,795	8,974	8,241
Cost of sales	[7]	(4,277)	(15,589)	(16,169)
Selling, informational and administrative expenses	[8]	(267)	(196)	(175)
Research and development expenses	[9]	219	272	314
Acquired in-process research and development expenses	[10]	(13)	(339)	(1,056)
Other income/(deductions)—net	[11]	$ 630	$ 664	$ 820

[1] See Note 1G.

[2] Earnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note 17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.

[3] Exclusive of amortization of intangible assets.

[4] See Notes 8A and 17A.

[5] Represents sales to our partners of products manufactured by us.

[6] Substantially all relates to amounts earned from our partners under co-promotion agreements. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis. The increase in 2022 was primarily driven by increases in Alliance revenues from Eliquis, Comirnaty and Bavencio.

[7] Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The decreases in 2023 and in 2022 primarily relate to Comirnaty.

[8] Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.

[9] Represents net reimbursements from our partners for research and development expenses incurred.

[10] Primarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.

[11] Primarily relates to royalties from our collaboration partners.